Ecto-NTPDase-Inhibitors

Inhibitors for use in human therapy Invention

The invention provides a new class of nucleosides exhibiting a high affinity for individual ecto-nucleotidetriphosphate-diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors).

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Prostate cancer organoids open path to precision oncology

A multi-institutional team of investigators led by bioengineer Ankur Singh has developed research tools that shed new light on a virtually untreatable form of prostate cancer, opening a pathway that may lead…

Experimental compound counters diabetic complications

An experimental compound reduced complications of type 1 and type 2 diabetes in mice – not by lowering blood sugar – but by countering its consequences: cell death, inflammation, and…

Taking new aim at COVID-19

The coronavirus’s tangled strands of RNA could offer new ways to treat people who get infected. To the untrained eye, the loops, kinks and folds in the single strand of…

Partners & Sponsors